These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35015310)

  • 1. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation.
    Abdallah NH; Habermann T; Buadi FK; Gertz MA; Lacy MQ; Rajkumar SV; Dingli D; Go RS; Hayman SR; Kumar SK; Kourelis T; Warsame R; Kapoor P; Muchtar E; Hwa YL; Fonder AL; Hobbs MA; Lin Y; Leung N; Binder M; Siddiqui MA; Kyle RA; Witzig TE; Dispenzieri A
    Am J Hematol; 2022 Apr; 97(4):401-410. PubMed ID: 35015310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
    Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
    Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
    Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
    Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndrome.
    Ganti AK; Pipinos I; Culcea E; Armitage JO; Tarantolo S
    Am J Hematol; 2005 Jul; 79(3):206-10. PubMed ID: 15981232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.
    Illerhaus G; Kasenda B; Ihorst G; Egerer G; Lamprecht M; Keller U; Wolf HH; Hirt C; Stilgenbauer S; Binder M; Hau P; Edinger M; Frickhofen N; Bentz M; Möhle R; Röth A; Pfreundschuh M; von Baumgarten L; Deckert M; Hader C; Fricker H; Valk E; Schorb E; Fritsch K; Finke J
    Lancet Haematol; 2016 Aug; 3(8):e388-97. PubMed ID: 27476790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Autologous Stem Cell Transplantation in Patients with Newly Diagnosed POEMS Syndrome.
    Li AA; Gao XM; Zhao H; Shen KN; Zhang L; Cao XX; Li J
    Transplant Cell Ther; 2024 Feb; 30(2):207.e1-207.e7. PubMed ID: 37931801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical spectrum of Castleman's disease.
    Dispenzieri A; Armitage JO; Loe MJ; Geyer SM; Allred J; Camoriano JK; Menke DM; Weisenburger DD; Ristow K; Dogan A; Habermann TM
    Am J Hematol; 2012 Nov; 87(11):997-1002. PubMed ID: 22791417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
    Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
    Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. R-High-CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY.
    Ogura M; Yamamoto K; Morishima Y; Wakabayashi M; Tobinai K; Ando K; Uike N; Kurosawa M; Gomyo H; Taniwaki M; Nosaka K; Tsukamoto N; Shimoyama T; Fukuhara N; Yakushijin Y; Ohnishi K; Miyazaki K; Sawada K; Takayama N; Hanamura I; Nagai H; Kobayashi H; Usuki K; Kobayashi N; Ohyashiki K; Utsumi T; Kumagai K; Maruyama D; Ohmachi K; Matsuno Y; Nakamura S; Hotta T; Tsukasaki K;
    Cancer Sci; 2018 Sep; 109(9):2830-2840. PubMed ID: 29957865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Herpesvirus Type 8-positive Multicentric Castleman Disease.
    Melikyan AL; Egorova EK; Julhakyan HL; Kovrigina AL; Savchenko VG
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S159-65. PubMed ID: 27133959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.
    Advani R; Warnke R; Rosenberg S
    Ann Oncol; 1999 Oct; 10(10):1207-9. PubMed ID: 10586338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
    Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
    Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China.
    Hu S; Li Z; Wang H; Chen L; Ma Y; Zhu X; Li J; Dong R; Yao W; Dong C; Zhang H; Li K; Dong K; Zhai X
    Eur J Pediatr; 2023 Dec; 182(12):5519-5530. PubMed ID: 37782352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.
    Madsen C; Pedersen MB; Vase MØ; Bendix K; Møller MB; Johansen P; Jensen BA; Jensen P; Munksgaard L; Brown PD; Segel EK; d'Amore FA
    Ann Oncol; 2015 Feb; 26(2):393-9. PubMed ID: 25411416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.